Werewolf Therapeutics Inc (HOWL) - Total Liabilities
Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) has total liabilities worth $50.01 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Werewolf Therapeutics Inc to assess how effectively this company generates cash.
Werewolf Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Werewolf Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Werewolf Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Werewolf Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Werewolf Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
G11 Resources Ltd
AU:G11
|
Australia | AU$161.95K |
|
WPP PLC
LSE:WPP
|
UK | GBX19.99 Billion |
|
US Energy Corp
NASDAQ:USEG
|
USA | $21.46 Million |
|
RedCloud Holdings plc Ordinary Shares
NASDAQ:RCT
|
USA | $21.41 Million |
|
INmune Bio Inc
NASDAQ:INMB
|
USA | $7.98 Million |
|
Culp, Inc. Common Stock
NYSE:CULP
|
USA | $70.53 Million |
|
Display Tech Co. Ltd
KQ:066670
|
Korea | ₩56.24 Billion |
|
Dabomb Protein
TWO:6578
|
Taiwan | NT$198.79 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Werewolf Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Werewolf Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Werewolf Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Werewolf Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Werewolf Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $53.54 Million | -15.63% |
| 2023-12-31 | $63.46 Million | +67.40% |
| 2022-12-31 | $37.91 Million | +43.25% |
| 2021-12-31 | $26.46 Million | +268.62% |
| 2020-12-31 | $7.18 Million | -39.72% |
| 2019-12-31 | $11.91 Million | -- |
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more